IRIS Institutional Research Information System - OPENBS Open Archive UniBS

Tomasoni, Daniela
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.339
AS - Asia 3.967
EU - Europa 1.946
SA - Sud America 958
Continente sconosciuto - Info sul continente non disponibili 119
AF - Africa 114
OC - Oceania 6
Totale 11.449
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.165
SG - Singapore 1.447
CN - Cina 918
BR - Brasile 795
HK - Hong Kong 561
IT - Italia 559
DE - Germania 321
VN - Vietnam 312
BD - Bangladesh 245
FR - Francia 176
FI - Finlandia 167
RU - Federazione Russa 164
GB - Regno Unito 159
TR - Turchia 137
IN - India 102
CA - Canada 83
IE - Irlanda 71
AR - Argentina 66
UA - Ucraina 65
MX - Messico 43
NL - Olanda 42
IQ - Iraq 40
JP - Giappone 38
ZA - Sudafrica 37
CZ - Repubblica Ceca 35
PL - Polonia 35
SA - Arabia Saudita 32
SE - Svezia 29
PK - Pakistan 28
AT - Austria 27
ES - Italia 24
EC - Ecuador 20
SC - Seychelles 20
CO - Colombia 19
VE - Venezuela 19
ID - Indonesia 16
MA - Marocco 16
KE - Kenya 13
EG - Egitto 11
PE - Perù 11
UZ - Uzbekistan 11
AE - Emirati Arabi Uniti 10
JM - Giamaica 10
PH - Filippine 10
BE - Belgio 9
CR - Costa Rica 9
LT - Lituania 9
TN - Tunisia 9
CL - Cile 8
JO - Giordania 8
PY - Paraguay 8
BG - Bulgaria 7
CH - Svizzera 7
NP - Nepal 7
TT - Trinidad e Tobago 7
UY - Uruguay 7
LV - Lettonia 6
MD - Moldavia 6
HN - Honduras 5
PA - Panama 5
AZ - Azerbaigian 4
MY - Malesia 4
PS - Palestinian Territory 4
RS - Serbia 4
BO - Bolivia 3
CY - Cipro 3
DO - Repubblica Dominicana 3
ET - Etiopia 3
HR - Croazia 3
KZ - Kazakistan 3
LA - Repubblica Popolare Democratica del Laos 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
PT - Portogallo 3
AU - Australia 2
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
DM - Dominica 2
DZ - Algeria 2
GY - Guiana 2
IL - Israele 2
KG - Kirghizistan 2
KH - Cambogia 2
KW - Kuwait 2
LB - Libano 2
MK - Macedonia 2
OM - Oman 2
RO - Romania 2
SV - El Salvador 2
SY - Repubblica araba siriana 2
TH - Thailandia 2
AL - Albania 1
AM - Armenia 1
AO - Angola 1
BB - Barbados 1
BY - Bielorussia 1
EE - Estonia 1
FJ - Figi 1
GR - Grecia 1
GT - Guatemala 1
Totale 11.315
Salva come PNG Salva come JPEG
Città #
Singapore 735
Hong Kong 559
Ashburn 495
San Jose 404
Beijing 261
The Dalles 259
New York 206
Los Angeles 174
Chandler 138
Lauterbourg 134
Council Bluffs 128
Helsinki 120
Columbus 119
Dallas 114
Istanbul 113
Ho Chi Minh City 111
Munich 106
Fairfield 104
Milan 89
Princeton 76
São Paulo 76
Dublin 71
Frankfurt am Main 69
Buffalo 68
Redondo Beach 61
Moscow 60
Hanoi 59
Chicago 57
Romola 55
Houston 49
Santa Clara 49
Shanghai 46
San Francisco 45
Orem 42
Woodbridge 40
Seattle 37
Wilmington 36
Montreal 34
Brescia 32
Cambridge 32
Tokyo 32
Brooklyn 30
Jacksonville 30
London 30
Phoenix 30
Rome 30
Atlanta 29
Chennai 28
Brno 26
Boston 25
Warsaw 25
Turku 24
Guangzhou 23
Ann Arbor 22
Haiphong 21
Washington 20
Nuremberg 19
Poplar 19
Toronto 19
Johannesburg 18
Lappeenranta 18
Belo Horizonte 17
Denver 17
Stockholm 17
Brasília 16
Düsseldorf 16
Amsterdam 15
Rio de Janeiro 15
City of London 14
Porto Alegre 14
Turin 14
Charlotte 13
Dhaka 13
Hangzhou 13
Mumbai 13
Baghdad 12
Da Nang 12
Kilburn 12
Las Vegas 12
Naples 12
Vienna 12
Biên Hòa 11
Buenos Aires 11
Curitiba 11
Erbil 11
Manchester 11
Salt Lake City 11
Salvador 11
Trieste 11
Catania 10
Mexico City 10
Nairobi 10
Newark 10
Querétaro 10
Riyadh 10
Ankara 9
Campinas 9
Kyiv 9
Brussels 8
Cape Town 8
Totale 6.451
Salva come PNG Salva come JPEG
Nome #
Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy 189
2024 update in heart failure 186
August 2020 at a glance: focus on neurohormonal antagonists and electrolytes 153
Association of Troponin Levels With Mortality in Italian Patients Hospitalized With Coronavirus Disease 2019: Results of a Multicenter Study 137
In-hospital and long-term mortality for acute heart failure: analysis at the time of admission to the emergency department 135
Acute heart failure: More questions than answers 135
How to tackle therapeutic inertia in heart failure with reduced ejection fraction. A scientific statement of the Heart Failure Association of the ESC 131
Clinical characteristics and outcome of acute heart failure patients with mid-range ejection fraction. 130
Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19) 122
The Mayo ATTR-CM score versus other diagnostic scores and cardiac biomarkers in patients with suspected cardiac amyloidosis 121
Advanced heart failure: guideline-directed medical therapy, diuretics, inotropes, and palliative care 119
The prognostic value of serial troponin measurements in patients admitted for COVID-19 118
Prevalence and clinical outcomes of isolated or combined moderate to severe mitral and tricuspid regurgitation in patients with cardiac amyloidosis 117
Biologically active adrenomedullin as a marker for residual congestion and early rehospitalization in patients hospitalized for acute heart failure: Data from STRONG-HF 117
Adherence and optimization of angiotensin converting enzyme inhibitor/angiotensin II receptors blockers and beta-blockers in patients hospitalized for acute heart failure 114
COVID 19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease 112
Machine learning for prediction of in-hospital mortality in coronavirus disease 2019 patients: results from an Italian multicenter study 110
Changes in Right Ventricular-to-Pulmonary Artery Coupling After Transcatheter Edge-to-Edge Repair in Secondary Mitral Regurgitation 110
Highlights in heart failure 109
Review: Evidence-Based Management of Acute Heart Failure 109
Prediction of mortality and heart failure hospitalisations in patients undergoing M-TEER: external validation of the COAPT risk score 107
Congestion in Patients with Advanced Heart Failure: Assessment and Treatment 103
Combined Role of Troponin and Natriuretic Peptides Measurements in Patients With Covid-19 (from the Cardio-COVID-Italy Multicenter Study) 102
Pulmonary embolism in patients with COVID-19: characteristics and outcomes in the Cardio-COVID Italy multicenter study 100
Titration of Medications After Acute Heart Failure Is Safe, Tolerated, and Effective Regardless of Risk 100
Right ventricular to pulmonary artery coupling and outcome in patients with cardiac amyloidosis 98
[Sodium-glucose cotransporter 2 inhibitors and heart failure with preserved ejection fraction: the EMPEROR-Preserved and DELIVER studies] 96
Medical therapy of cardiogenic shock: Contemporary use of inotropes and vasopressors 96
Impact of COVID-2019 outbreak on prevalence, clinical presentation and outcomes of ST-elevation myocardial infarction 96
Implications of atrial fibrillation on the clinical course and outcomes of hospitalized COVID-19 patients: results of the Cardio-COVID-Italy multicentre study 95
Impact on clinical outcomes of right ventricular response to percutaneous correction of secondary mitral regurgitation 95
Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID-19. Results of the Cardio-COVID-Italy multicentre study 94
Prognostic impact of the updated 2018 HFA-ESC definition of advanced heart failure: results from the HELP-HF registry 94
COVID-19 and Heart Failure: From Epidemiology During the Pandemic to Myocardial Injury, Myocarditis, and Heart Failure Sequelae 94
[Empagliflozin and heart failure: the EMPEROR-Reduced trial] 93
Telemedicine for the treatment of heart failure: new opportunities after COVID-19 92
April 2022 at a glance: focus on prevention, acute heart failure and heart failure with preserved ejection fraction 92
Echocardiographic findings in subjects with an amyloidogenic apolipoprotein A1 pathogenic variant 92
Characteristics and outcomes of patients with tricuspid regurgitation and advanced heart failure 91
[Transcatheter devices for chronic heart failure: state of the art] 91
2023 focused update of the 2021 ESC heart failure guidelines: Key messages for clinical practice 91
Frailty according to the 2019 HFA-ESC definition in patients at risk for advanced heart failure: Insights from the HELP-HF registry 90
Prognostic value of right ventricular longitudinal strain in patients with secondary mitral regurgitation undergoing transcatheter edge-to-edge mitral valve repair 89
Prognostic significance of serum potassium in patients hospitalized for acute heart failure 89
Impact of Transcatheter Edge-to-Edge Mitral Valve Repair on Guideline-Directed Medical Therapy Uptitration 89
Impact of malnutrition in patients with severe heart failure 89
[Diagnostic-therapeutic care pathways for patients with cardiac amyloidosis - SIC/ANMCO Consensus document. Edited by the Italian Cardiac Amyloidosis Network (RIAC)] 89
August 2021 at a glance: focus on cardiomyopathies, medical treatment and devices 89
Sodium glucose co-transporter 2 inhibitors and quality of life in patients with heart failure: a comprehensive systematic review and meta-analysis of randomized controlled trials 88
Sex-related differences in patients with coronavirus disease 2019: results of the Cardio-COVID-Italy multicentre study 88
Cardiac contractility modulation: an effective treatment strategy for heart failure beyond reduced left ventricular ejection fraction? 87
July 2021 at a glance: focus on blood volume distribution, haemodynamics and adherence to therapy 87
Determinants of the protective effect of glucocorticoids on mortality in hospitalized patients with COVID-19: Insights from the Cardio-COVID-Italy multicenter study 86
A year in heart failure: an update of recent findings 86
July 2020 at a glance: focus on imaging and cardiomyopathies 85
Aiming at harmony. Comparing and contrasting International HFrEF Guidelines 84
Predicting survival in patients with severe heart failure: Risk score validation in the HELP-HF cohort 84
Heart failure: an update from the last years and a look at the near future 83
Left ventricular wall thickness and severity of cardiac disease in women and men with transthyretin amyloidosis 83
Updates in heart failure: sodium glucose co-transporter 2 inhibitors and beyond - major changes are coming 82
Pre-discharge and early post-discharge management of patients hospitalized for acute heart failure: A scientific statement by the Heart Failure Association of the ESC 82
Evolution of tricuspid regurgitation after transcatheter edge-to-edge mitral valve repair for secondary mitral regurgitation and its impact on mortality 81
Value of the HFA-PEFF and H2 FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis 80
September 2021 at a glance: focus on biomarkers, sex differences and adherence to medical treatment 79
September 2020 at a glance: focus on heart failure with preserved ejection fraction and medical therapy 79
Treating amyloid transthyretin cardiomyopathy: lessons learned from clinical trials 78
Guideline-directed medical therapy in severe heart failure with reduced ejection fraction: an analysis from the HELP-HF registry 78
Blood pressure and intensive treatment up-titration after acute heart failure hospitalization: Insights from the STRONG-HF trial 78
Direct Oral Anticoagulants for the Treatment of Left Ventricular Thrombus-A New Indication? A Meta-summary of Case Reports. 78
Heart failure in the last year: progress and perspective 77
Impact and predictors of device-related thrombus after percutaneous left atrial appendage closure 77
Coronavirus disease 2019 and cardiovascular disease: what we have learnt during the last 2 years 75
SGLT2 Inhibitor Therapy in Patients With Transthyretin Amyloid Cardiomyopathy 74
Impact of Pulmonary Hypertension on Outcomes after Transcatheter Tricuspid Valve Edge-to-Edge Repair 74
Clinical and prognostic implications of heart failure hospitalization in patients with advanced heart failure 73
Characteristics, treatment, and outcomes of early vs. late enrollees of the STRONG-HF trial 72
Clinical Phenotype and Prognosis of Asymptomatic Patients With Transthyretin Cardiac Amyloid Infiltration 71
Multimodality imaging in the diagnostic management of concomitant aortic stenosis and transthyretin-related wild-type cardiac amyloidosis 71
August 2022 at a glance: focus on heart failure with preserved ejection fraction and cardiac amyloidosis 71
April 2023 at a glance: focus on diagnosis and comorbidities 70
Obesity, heart failure with preserved ejection fraction, and the role of glucagon-like peptide-1 receptor agonists 70
Sacubitril/valsartan in real-life European patients with heart failure and reduced ejection fraction: a systematic review and meta-analysis 69
Myocardial Involvement in COVID-19: an Interaction Between Comorbidities and Heart Failure with Preserved Ejection Fraction. A Further Indication of the Role of Inflammation 68
Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology 68
Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC-TIVE study, an Italian nationwide survey 67
Prognostic Benefit of New Drugs for HFrEF: A Systematic Review and Network Meta-Analysis 67
Prognostic role of TAPSE to PASP ratio in outpatients with left ventricular systolic dysfunction 66
Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM-AHF trial 66
Real-world candidacy to mavacamten in a contemporary hypertrophic obstructive cardiomyopathy population 66
NT-proBNP and high-intensity care for acute heart failure: the STRONG-HF trial 66
Clinical burden and predictors of non-cardiovascular mortality and morbidity in advanced heart failure 65
Optimization of Evidence-Based Heart Failure Medications After an Acute Heart Failure Admission: A Secondary Analysis of the STRONG-HF Randomized Clinical Trial 65
Ischemic Etiology in Advanced Heart Failure: Insight from the HELP-HF Registry 65
Detailed Assessment of the "I Need Help" Criteria in Patients With Heart Failure: Insights From the HELP-HF Registry 64
The role of multimorbidity in patients with heart failure across the left ventricular ejection fraction spectrum: Data from the Swedish Heart Failure Registry 64
Device-based percutaneous treatments to decompress the left atrium in heart failure with preserved ejection fraction 64
Management of hypertrophic cardiomyopathy 62
January 2022 at a glance: time for the new ESC guidelines on heart failure 61
Cardiac resynchronization therapy for enabling guideline-directed medical therapy optimization in heart failure 61
Uptitrating Treatment After Heart Failure Hospitalization Across the Spectrum of Left Ventricular Ejection Fraction 61
Totale 9.056
Salva come PNG Salva come JPEG
Categoria #
all - tutte 77.709
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 77.709
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022157 0 0 4 6 8 6 8 10 14 10 18 73
2022/2023486 59 36 8 18 36 137 7 32 73 15 31 34
2023/20241.152 59 13 106 90 74 136 82 23 278 38 43 210
2024/20252.595 21 28 95 247 247 229 283 124 212 271 486 352
2025/20266.020 567 767 480 871 502 377 727 306 408 495 339 181
2026/2027617 321 212 84 0 0 0 0 0 0 0 0 0
Totale 11.449